{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["De Santis F"],"pubmed_abstract":["Minor ischemic strokes, usually defined as acute ischemic strokes with National Institutes of Health Stroke Scale score ≤5, account for over half of all cases and are often underestimated due to initially mild symptoms. Yet up to 30% of patients develop disability within 90 days, challenging the notion of a benign course. This guidance offers a pragmatic, scenario-based framework for acute minor ischemic stroke management, considering symptom severity (disabling versus nondisabling), eligibility for reperfusion, and presence of large vessel occlusion. Drawing from randomized trials, real-world evidence, and international guidelines, we examine therapeutic strategies, including dual antiplatelet therapy with aspirin plus a P2Y<sub>12</sub> inhibitor, anticoagulation, intravenous thrombolysi"],"journal":["Stroke"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12829504"],"repository":["biostudies-literature"],"pubmed_title":["Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians."],"pmcid":["PMC12829504"],"pubmed_authors":["Foschi M","D'Anna L","Fischer U","Pontes-Neto OM","Turc G","Khatri P","Coutts SB","De Santis F","Sandset EC","Tsivgoulis G","Sacco S","Nasreldein A","Nguyen TN"],"additional_accession":[]},"is_claimable":false,"name":"Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians.","description":"Minor ischemic strokes, usually defined as acute ischemic strokes with National Institutes of Health Stroke Scale score ≤5, account for over half of all cases and are often underestimated due to initially mild symptoms. Yet up to 30% of patients develop disability within 90 days, challenging the notion of a benign course. This guidance offers a pragmatic, scenario-based framework for acute minor ischemic stroke management, considering symptom severity (disabling versus nondisabling), eligibility for reperfusion, and presence of large vessel occlusion. Drawing from randomized trials, real-world evidence, and international guidelines, we examine therapeutic strategies, including dual antiplatelet therapy with aspirin plus a P2Y<sub>12</sub> inhibitor, anticoagulation, intravenous thrombolysi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T22:05:18.109Z","creation":"2026-06-05T03:12:21.5Z"},"accession":"S-EPMC12829504","cross_references":{"pubmed":["41376587"],"doi":["10.1161/STROKEAHA.125.053504"]}}